SARS-CoV-2 Ct values and COVID-19 symptoms in patients with haematological malignancies in South Africa

Bibliographic Details
Title: SARS-CoV-2 Ct values and COVID-19 symptoms in patients with haematological malignancies in South Africa
Authors: Keitumetsi L. Sothoane, Sarah A. Van Blydenstein, Vinitha Philip, Jeannette Wadula
Source: Southern African Journal of Infectious Diseases, Vol 40, Iss 1, Pp e1-e9 (2025)
Publisher Information: AOSIS, 2025.
Publication Year: 2025
Collection: LCC:Infectious and parasitic diseases
Subject Terms: severe acute respiratory syndrome coronavirus 2 (sars-cov-2), covid-19, cycle threshold value, haematological malignancies, symptoms, viral shedding, chemotherapy, Infectious and parasitic diseases, RC109-216
More Details: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase polymerase chain reaction (RT-PCR) cycle threshold (Ct) values serve as surrogate markers for estimating viral load. Their usefulness in patients with haematological malignancies and COVID-19 has not been studied in the South African context. Objectives: To evaluate if a Ct value 30 can predict COVID-19 symptom development in adult patients with haematological malignancies. Method: A retrospective cohort study on adult patients with haematological malignancies and COVID-19 was conducted at Chris Hani Baragwanath Academic Hospital from 01 July 2020 to 31 July 2021. The relationship between Ct values, symptoms and disease severity, along with changes over time were evaluated. Results: Among 53 patients (50.9% male, median age of 38 years), Ct values 30 did not significantly predict COVID-19 symptom development (p = 0.417). However, severe disease correlated with lower Ct values (p = 0.002). No significant difference in the duration (days) from positive to negative tests was found between symptomatic and asymptomatic patients, and by severity of disease in the symptomatic patients. Lymphopenia was associated with severe disease, and those with lymphoid malignancies experienced longer viral shedding. Conclusion: Patients with haematological malignancies can exhibit symptoms at any Ct value but lower Ct values indicate more severe disease. This information can be critical for chemotherapy timing to minimize adverse outcomes. Contribution: The findings suggest a potential benefit in delaying chemotherapy at any Ct value as patients could present with acute SARS-CoV-2 infection at higher Ct values, and therefore face increased risk of adverse outcomes with early chemotherapy initiation.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2312-0053
2313-1810
Relation: https://sajid.co.za/index.php/sajid/article/view/676; https://doaj.org/toc/2312-0053; https://doaj.org/toc/2313-1810
DOI: 10.4102/sajid.v40i1.676
Access URL: https://doaj.org/article/bd0abd77df3f499e8f106d8615cecac3
Accession Number: edsdoj.bd0abd77df3f499e8f106d8615cecac3
Database: Directory of Open Access Journals
More Details
ISSN:23120053
23131810
DOI:10.4102/sajid.v40i1.676
Published in:Southern African Journal of Infectious Diseases
Language:English